{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T19:03:25Z","timestamp":1774551805849,"version":"3.50.1"},"reference-count":86,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T00:00:00Z","timestamp":1710892800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Open Respiratory Archives"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.opresp.2024.100323","type":"journal-article","created":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T23:33:47Z","timestamp":1712360027000},"page":"100323","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Advances in Immunotherapy for Malignant Pleural Mesothelioma: From Emerging Strategies to Translational Insights"],"prefix":"10.1016","volume":"6","author":[{"given":"Rafael","family":"L\u00f3pez-Castro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1lvaro","family":"Fuentes-Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Medina del Valle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tania","family":"Garc\u00eda Pe\u00f1a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Soro Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leticia","family":"L\u00f3pez Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1ngel","family":"Cilleruelo Ramos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.opresp.2024.100323_bib0435","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.annonc.2021.11.019","article-title":"Malignant pleural mesothelioma: new guidelines make us stronger for defeating this disease","volume":"33","author":"Remon","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.opresp.2024.100323_bib0440","first-page":"70","article-title":"Mesothelioma: a review","volume":"12","author":"Mott","year":"2012","journal-title":"Ochsner J"},{"key":"10.1016\/j.opresp.2024.100323_bib0445","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0226-2020","article-title":"Update on biology and management of mesothelioma","volume":"30","author":"Asciak","year":"2021","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.opresp.2024.100323_bib0450","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.ccm.2021.08.006","article-title":"Malignant pleural mesothelioma: updates for respiratory physicians","volume":"42","author":"Sidhu","year":"2021","journal-title":"Clin Chest Med"},{"key":"10.1016\/j.opresp.2024.100323_bib0455","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1007\/s12094-020-02532-2","article-title":"SEOM clinical guidelines for the treatment of malignant pleural mesothelioma (2020)","volume":"23","author":"Nadal","year":"2021","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.opresp.2024.100323_bib0460","doi-asserted-by":"crossref","first-page":"743","DOI":"10.2147\/CLEP.S105396","article-title":"Mesothelioma in the United States: a Surveillance, Epidemiology, and End Results (SEER)-Medicare investigation of treatment patterns and overall survival","volume":"8","author":"Beebe-Dimmer","year":"2016","journal-title":"Clin Epidemiol"},{"key":"10.1016\/j.opresp.2024.100323_bib0465","doi-asserted-by":"crossref","first-page":"102265","DOI":"10.1016\/j.ctrv.2021.102265","article-title":"Pleural mesothelioma (PM) \u2013 the status of systemic therapy","volume":"100","author":"Cui","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.opresp.2024.100323_bib0470","series-title":"National Mesothelioma Audit report 2020 (audit period 2016\u201318)","author":"Audit","year":"2020"},{"key":"10.1016\/j.opresp.2024.100323_bib0475","doi-asserted-by":"crossref","first-page":"716","DOI":"10.2471\/BLT.11.086678","article-title":"Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008","volume":"89","author":"Delgermaa","year":"2011","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.opresp.2024.100323_bib0480","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1245\/s10434-021-09589-5","article-title":"Landmark trials in the surgical management of mesothelioma","volume":"28","author":"Kantor","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.opresp.2024.100323_bib0485","article-title":"Malignant pleural mesothelioma: an update","volume":"47","author":"Hajj","year":"2021","journal-title":"J Bras Pneumol"},{"key":"10.1016\/j.opresp.2024.100323_bib0490","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13061440","article-title":"CTLA-4 in regulatory T cells for cancer immunotherapy","volume":"13","author":"Sobhani","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.opresp.2024.100323_bib0495","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.bcp.2016.07.012","article-title":"New therapeutic strategies for malignant pleural mesothelioma","volume":"123","author":"Bonelli","year":"2017","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.opresp.2024.100323_bib0500","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nri.2017.108","article-title":"The diverse functions of the PD1 inhibitory pathway","volume":"18","author":"Sharpe","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.opresp.2024.100323_bib0505","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J Exp Med"},{"key":"10.1016\/j.opresp.2024.100323_bib0510","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S2213-2600(15)00092-2","article-title":"Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study","volume":"3","author":"Calabro","year":"2015","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.opresp.2024.100323_bib0515","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/0008-5472.CAN-14-1008","article-title":"Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma","volume":"75","author":"Guo","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.opresp.2024.100323_bib0520","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/ijc.23949","article-title":"Genomic events associated with progression of pleural malignant mesothelioma","volume":"124","author":"Ivanov","year":"2009","journal-title":"Int J Cancer"},{"key":"10.1016\/j.opresp.2024.100323_bib0525","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1183\/09059180.00007014","article-title":"Malignant pleural mesothelioma: history, controversy and future of a manmade epidemic","volume":"24","author":"Roe","year":"2015","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.opresp.2024.100323_bib0530","first-page":"2108","article-title":"Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas","volume":"9","author":"Illei","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.opresp.2024.100323_bib0535","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19040988","article-title":"NF2\/merlin inactivation and potential therapeutic targets in mesothelioma","volume":"19","author":"Sato","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.opresp.2024.100323_bib0540","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.lungcan.2008.08.014","article-title":"Functional inactivation of NF2\/merlin in human mesothelioma","volume":"64","author":"Thurneysen","year":"2009","journal-title":"Lung Cancer"},{"key":"10.1016\/j.opresp.2024.100323_bib0545","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1158\/2159-8290.CD-18-0804","article-title":"Integrative molecular characterization of malignant pleural mesothelioma","volume":"8","author":"Hmeljak","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.opresp.2024.100323_bib0550","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/ng.3520","article-title":"Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations","volume":"48","author":"Bueno","year":"2016","journal-title":"Nat Genet"},{"key":"10.1016\/j.opresp.2024.100323_bib0555","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/ng.912","article-title":"Germline BAP1 mutations predispose to malignant mesothelioma","volume":"43","author":"Testa","year":"2011","journal-title":"Nat Genet"},{"key":"10.1016\/j.opresp.2024.100323_bib0560","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41568-020-0265-y","article-title":"Tumour predisposition and cancer syndromes as models to study gene-environment interactions","volume":"20","author":"Carbone","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.opresp.2024.100323_bib0565","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.79.0352","article-title":"A subset of mesotheliomas with improved survival occurring in carriers of BAP1 and other germline mutations","volume":"36","author":"Pastorino","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.opresp.2024.100323_bib0570","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/onc.2015.125","article-title":"Role of Merlin\/NF2 inactivation in tumor biology","volume":"35","author":"Petrilli","year":"2016","journal-title":"Oncogene"},{"key":"10.1016\/j.opresp.2024.100323_bib0575","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222112071","article-title":"Insights into intra-tumoral heterogeneity: transcriptional profiling of chemoresistant MPM cell subpopulations reveals involvement of NFkB and DNA repair pathways and contributes a prognostic signature","volume":"22","author":"Cioce","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.opresp.2024.100323_bib0580","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1159\/000499677","article-title":"The value of COX-2, NF-kappaB, and blood routine indexes in the prognosis of malignant peritoneal mesothelioma","volume":"42","author":"Yin","year":"2019","journal-title":"Oncol Res Treat"},{"key":"10.1016\/j.opresp.2024.100323_bib0585","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1093\/carcin\/bgz004","article-title":"Prognostic factors of survival in patients with malignant pleural mesothelioma: an analysis of the National Cancer Database","volume":"40","author":"Van Gerwen","year":"2019","journal-title":"Carcinogenesis"},{"issue":"Suppl. 5","key":"10.1016\/j.opresp.2024.100323_bib0590","doi-asserted-by":"crossref","first-page":"v31","DOI":"10.1093\/annonc\/mdv199","article-title":"Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Baas","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.opresp.2024.100323_bib0595","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.annonc.2021.11.005","article-title":"Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"33","author":"Popat","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.opresp.2024.100323_bib0600","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00953-2019","article-title":"ERS\/ESTS\/EACTS\/ESTRO guidelines for the management of malignant pleural mesothelioma","volume":"55","author":"Scherpereel","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.opresp.2024.100323_bib0605","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.opresp.2024.100323_bib0610","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1158\/1078-0432.CCR-21-1466","article-title":"FDA approval summary: nivolumab in combination with ipilimumab for the treatment of unresectable malignant pleural mesothelioma","volume":"28","author":"Nakajima","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.opresp.2024.100323_bib0615","series-title":"Nivolumab\/ipilimumab takes step toward EU approval in frontline malignant pleural mesothelioma","author":"Rosa","year":"2020"},{"key":"10.1016\/j.opresp.2024.100323_bib0620","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1200\/JCO.21.01567","article-title":"New era for malignant pleural mesothelioma: updates on therapeutic options","volume":"40","author":"Tsao","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.opresp.2024.100323_bib0625","doi-asserted-by":"crossref","first-page":"101432","DOI":"10.1016\/j.eclinm.2022.101432","article-title":"Active symptom control with or without oral vinorelbine in patients with relapsed malignant pleural mesothelioma (VIM): a randomised, phase 2 trial","volume":"48","author":"Fennell","year":"2022","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.opresp.2024.100323_bib0630","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.lungcan.2008.04.001","article-title":"The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma","volume":"63","author":"Stebbing","year":"2009","journal-title":"Lung Cancer"},{"key":"10.1016\/j.opresp.2024.100323_bib0635","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/COC.0b013e3181cae90e","article-title":"Phase II study of gemcitabine plus docetaxel as second-line treatment in malignant pleural mesothelioma: a single institution study","volume":"34","author":"Tourkantonis","year":"2011","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.opresp.2024.100323_bib0640","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.lungcan.2014.03.006","article-title":"Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma","volume":"84","author":"Zauderer","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.opresp.2024.100323_bib0645","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.lungcan.2013.11.011","article-title":"Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma","volume":"84","author":"Zucali","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.opresp.2024.100323_bib0650","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.lungcan.2011.08.011","article-title":"Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey","volume":"75","author":"Zucali","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.opresp.2024.100323_bib0655","doi-asserted-by":"crossref","first-page":"e0121071","DOI":"10.1371\/journal.pone.0121071","article-title":"Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM)","volume":"10","author":"Cedres","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.opresp.2024.100323_bib0660","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1097\/JTO.0000000000000177","article-title":"B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis","volume":"9","author":"Mansfield","year":"2014","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.opresp.2024.100323_bib0665","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/S1470-2045(13)70381-4","article-title":"Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial","volume":"14","author":"Calabro","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.opresp.2024.100323_bib0670","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(17)30446-1","article-title":"Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial","volume":"18","author":"Maio","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.opresp.2024.100323_bib0675","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jamaoncol.2018.5428","article-title":"Efficacy and safety of avelumab treatment in patients with advanced unresectable mesothelioma: phase 1b results from the JAVELIN solid tumor trial","volume":"5","author":"Hassan","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.opresp.2024.100323_bib0680","doi-asserted-by":"crossref","first-page":"S294","DOI":"10.1016\/j.jtho.2016.11.302","article-title":"OA13.03 long-term overall survival for patients with malignant pleural mesothelioma on pembrolizumab enrolled in KEYNOTE-028","volume":"12","author":"Alley","year":"2017","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.opresp.2024.100323_bib0685","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S1470-2045(17)30169-9","article-title":"Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial","volume":"18","author":"Alley","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.opresp.2024.100323_bib0690","doi-asserted-by":"crossref","first-page":"S339","DOI":"10.1016\/j.jtho.2018.08.277","article-title":"OA08.03 phase II trial of pembrolizumab (NCT02399371) in previously-treated malignant mesothelioma (MM): final analysis","volume":"13","author":"Desai","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.opresp.2024.100323_bib0695","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1016\/j.jtho.2018.08.007","article-title":"Pembrolizumab as palliative immunotherapy in malignant pleural mesothelioma","volume":"13","author":"Metaxas","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.opresp.2024.100323_bib0700","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/j.annonc.2020.09.009","article-title":"A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial","volume":"31","author":"Popat","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.opresp.2024.100323_bib0705","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.jtho.2018.05.038","article-title":"Programmed death 1 blockade with nivolumab in patients with recurrent malignant pleural mesothelioma","volume":"13","author":"Quispel-Janssen","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.opresp.2024.100323_bib0710","doi-asserted-by":"crossref","first-page":"5485","DOI":"10.1158\/1078-0432.CCR-19-0103","article-title":"Clinical efficacy and safety of nivolumab: results of a multicenter, open-label, single-arm, Japanese phase II study in Malignant Pleural Mesothelioma (MERIT)","volume":"25","author":"Okada","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.opresp.2024.100323_bib0715","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(18)30765-4","article-title":"Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial","volume":"20","author":"Scherpereel","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.opresp.2024.100323_bib0720","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S2213-2600(18)30420-X","article-title":"Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial","volume":"7","author":"Disselhorst","year":"2019","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.opresp.2024.100323_bib0725","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/S1470-2045(21)00471-X","article-title":"Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial","volume":"22","author":"Fennell","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.opresp.2024.100323_bib0730","doi-asserted-by":"crossref","first-page":"103639","DOI":"10.1016\/j.critrevonc.2022.103639","article-title":"A systematic review and meta-analysis of trials assessing PD-1\/PD-L1 immune checkpoint inhibitors activity in pre-treated advanced stage malignant mesothelioma","volume":"172","author":"Tagliamento","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.opresp.2024.100323_bib0735","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1038\/s41591-021-01541-0","article-title":"Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial","volume":"27","author":"Forde","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.opresp.2024.100323_bib0740","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/S1470-2045(20)30462-9","article-title":"Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in","volume":"21","author":"Nowak","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.opresp.2024.100323_bib0745","doi-asserted-by":"crossref","first-page":"e057663","DOI":"10.1136\/bmjopen-2021-057663","article-title":"Protocol of DREAM3R: DuRvalumab with chEmotherapy as first-line treAtment in advanced pleural Mesothelioma-a phase 3 randomised trial","volume":"12","author":"Kok","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.opresp.2024.100323_bib0750","unstructured":"NCT03762018: BEAT-meso: bevacizumab and atezolizumab in malignant pleural mesothelioma. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03762018."},{"key":"10.1016\/j.opresp.2024.100323_bib0755","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.jtho.2023.02.003","article-title":"Brief report: canadian cancer trials group IND.227: a phase 2 randomized study of pembrolizumab in patients with advanced malignant pleural mesothelioma (NCT02784171)","volume":"18","author":"Piccirillo","year":"2023","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.opresp.2024.100323_bib0760","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA8505","article-title":"IND227 phase III (P3) study of cisplatin\/pemetrexed (CP) with or without pembrolizumab (pembro) in patients (pts) with malignant pleural mesothelioma (PM): A CCTG, NCIN, and IFCT trial","volume":"41","author":"Chu","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.opresp.2024.100323_bib0765","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/COC.0000000000000239","article-title":"CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition","volume":"39","author":"Buchbinder","year":"2016","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.opresp.2024.100323_bib0770","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S2213-2600(18)30151-6","article-title":"Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study","volume":"6","author":"Calabro","year":"2018","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.opresp.2024.100323_bib0775","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.annonc.2022.01.074","article-title":"First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743","volume":"33","author":"Peters","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.opresp.2024.100323_bib0780","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.opresp.2024.100323_bib0785","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) Mesothelioma: Pleural. 2023."},{"key":"10.1016\/j.opresp.2024.100323_bib0790","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.opresp.2024.100323_bib0795","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS8591","article-title":"Phase III study with atezolizumab versus placebo in patients with malignant pleural mesothelioma after pleurectomy\/decortication (AtezoMeso study)","volume":"40","author":"Pagano","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.opresp.2024.100323_bib0800","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.1200\/JCO.2016.68.3672","article-title":"Mesothelin immunotherapy for cancer: ready for prime time?","volume":"34","author":"Hassan","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.opresp.2024.100323_bib0805","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40364-021-00264-1","article-title":"Anti-Mesothelin CAR T cell therapy for malignant mesothelioma","volume":"9","author":"Castelletti","year":"2021","journal-title":"Biomark Res"},{"key":"10.1016\/j.opresp.2024.100323_bib0810","first-page":"133","article-title":"Oncolytic virotherapy for human malignant mesothelioma: recent advances","volume":"4","author":"Boisgerault","year":"2015","journal-title":"Oncolytic Virother"},{"key":"10.1016\/j.opresp.2024.100323_bib0815","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.7150\/jca.71992","article-title":"From immunosuppression to immunomodulation \u2013 turning cold tumours into hot","volume":"13","author":"Garofalo","year":"2022","journal-title":"J Cancer"},{"key":"10.1016\/j.opresp.2024.100323_bib0820","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1112960","article-title":"Correlative analysis from a phase I clinical trial of intrapleural administration of oncolytic vaccinia virus (Olvi-vec) in patients with malignant pleural mesothelioma","volume":"14","author":"Chintala","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.opresp.2024.100323_bib0825","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3389\/fonc.2017.00179","article-title":"Oncolytic viral therapy for mesothelioma","volume":"7","author":"Pease","year":"2017","journal-title":"Front Oncol"},{"key":"10.1016\/j.opresp.2024.100323_bib0830","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.lungcan.2020.10.007","article-title":"Oncolytic herpesvirus therapy for mesothelioma \u2013 a phase I\/IIa trial of intrapleural administration of HSV1716","volume":"150","author":"Danson","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.opresp.2024.100323_bib0835","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s12890-021-01513-7","article-title":"Emerging avenues in immunotherapy for the management of malignant pleural mesothelioma","volume":"21","author":"Gray","year":"2021","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.opresp.2024.100323_bib0840","doi-asserted-by":"crossref","first-page":"4547","DOI":"10.1158\/1078-0432.CCR-07-0708","article-title":"Peptide epitopes from the Wilms\u2019 tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells","volume":"13","author":"May","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.opresp.2024.100323_bib0845","first-page":"7483","article-title":"A randomized phase II trial of adjuvant Galinpepimut-S, WT-1 analogue peptide vaccine, after multimodality therapy for patients with malignant pleural mesothelioma","volume":"23","author":"Zauderer","year":"2017","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.opresp.2024.100323_bib0850","first-page":"1168","article-title":"Immunotherapy of murine malignant mesothelioma using tumor lysate-pulsed dendritic cells","volume":"171","author":"Hegmans","year":"2005","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.opresp.2024.100323_bib0855","article-title":"Long-term follow-up of mesothelioma patients treated with dendritic cell therapy in three phase I\/II trials","volume":"9","author":"Dumoulin","year":"2021","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.opresp.2024.100323_bib0860","first-page":"1383","article-title":"Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma","volume":"181","author":"Hegmans","year":"2010","journal-title":"Arch Bronconeumol"}],"container-title":["Open Respiratory Archives"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2659663624000262?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2659663624000262?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T13:42:33Z","timestamp":1733406153000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2659663624000262"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":86,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S2659663624000262"],"URL":"https:\/\/doi.org\/10.1016\/j.opresp.2024.100323","relation":{},"ISSN":["2659-6636"],"issn-type":[{"value":"2659-6636","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in Immunotherapy for Malignant Pleural Mesothelioma: From Emerging Strategies to Translational Insights","name":"articletitle","label":"Article Title"},{"value":"Open Respiratory Archives","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.opresp.2024.100323","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Sociedad Espa\u00f1ola de Neumolog\u00eda y Cirug\u00eda Tor\u00e1cica (SEPAR). Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"100323"}}